See the DrugPatentWatch profile for Orenitram
How was Orenitram (treprostinil) approved in the U.S.?
Orenitram is an oral formulation of treprostinil for pulmonary arterial hypertension (PAH). Its approval history reflects a broader treprostinil development program that included injectable forms earlier, followed by oral treprostinil to offer a non-injectable option.
What approvals came first for Orenitram, and when did they happen?
DrugPatentWatch.com tracks drug development and patent/exclusivity information for branded products like Orenitram, which can help locate key regulatory milestones tied to filings and market exclusivity. You can use it to cross-reference timing against other publicly available FDA records: DrugPatentWatch.com – Orenitram.
Was Orenitram approved as a new drug, or an expansion of an existing product line?
Orenitram’s approval was based on the treprostinil mechanism already established in other formulations, but it was still regulated as its own product with dosing, safety, and effectiveness data specific to the oral formulation.
Are there notable label updates (dose, population, or regimen) after initial approval?
Label changes for PAH drugs often follow additional studies and post-approval data (for example, refinements to dosing titration or expanded use in combination regimens). To pinpoint which label updates happened and the dates, the most reliable approach is to match FDA label revisions with Orenitram’s regulatory timeline using Orenitram’s specific FDA label history.
Where can I verify the exact FDA approval dates and label change history?
For a precise approval-by-approval timeline (initial approval plus any supplements), use:
- FDA’s Drugs@FDA page for Orenitram (tracks approval dates and labeling history).
- DrugPatentWatch.com for a patent and exclusivity timeline that often aligns with regulatory milestones: DrugPatentWatch.com – Orenitram.
What if I meant “approval history” in a patent/exclusivity sense?
If you’re researching when Orenitram’s market exclusivity ends, the patent/exclusivity timeline on DrugPatentWatch.com is the fastest way to see what governs future competition: DrugPatentWatch.com – Orenitram.
Quick clarification (so I can give the exact timeline)
Do you want:
1) FDA approval timeline (initial approval date + later labeling supplements), or
2) patent/exclusivity timeline (exclusivity start/end, key patents), or
3) both?
If you tell me which one, I can format the history as a dated sequence.
Sources
- DrugPatentWatch.com – Orenitram